Ovarian Cancer Stage IV Clinical Trial
Official title:
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.
For the treatment of advanced ovarian cancer, the decision to undergo primary surgery is complex and decided by the surgeon while multiple considering multiple elements. Sometimes, chemotherapy is needed before surgery to shrink some of the tumours. To choose the best patients for primary surgery, several prediction tools have been developed. CT and MRI have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumours can be safely removed by surgery. However, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process. With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, the investigators would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumours can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. The investigators will enroll patients at a one-time point (being the time of surgery) and follow them forward in time and There will be no additional visits other than the surgery. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
Completed |
NCT00945191 -
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT03579394 -
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT04701645 -
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT03126812 -
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03922776 -
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
|
N/A | |
Completed |
NCT03085238 -
Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT04938583 -
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05479045 -
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
|
Phase 2 | |
Completed |
NCT05005650 -
Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
|
||
Recruiting |
NCT03899610 -
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
|
Phase 2 | |
Recruiting |
NCT04789694 -
Prehabilitation in Gynaecological Cancer Patients
|
Phase 3 | |
Not yet recruiting |
NCT05187208 -
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
|
Phase 4 | |
Recruiting |
NCT06272240 -
Tumor Microenvironment in Ovarian Cancer
|
||
Not yet recruiting |
NCT06268665 -
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
|
Phase 2 | |
Active, not recruiting |
NCT03275506 -
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
|
Phase 2 | |
Recruiting |
NCT06290193 -
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
|
Phase 2 | |
Completed |
NCT02258165 -
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
|
||
Recruiting |
NCT03693248 -
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer
|
Phase 3 |